Episode Details
Back to EpisodesCardiol Therapeutics ($CRDL): A New Approach to Treating Inflammation in Heart Disease
Season 2026
Episode 819
Published 2 weeks, 1 day ago
Description
This interview is disseminated on behalf of Cardiol Therapeutics Inc.
In this episode of Stocks to Watch, we sit down with David Elsley, President and CEO of Cardiol Therapeutics (NASDAQ: CRDL | TSX: CRDL), to discuss the company's late-stage clinical development program targeting inflammation-driven heart conditions, including recurrent pericarditis and acute myocarditis.
Learn more: https://www.cardiolrx.com
Watch the full YouTube interview here: https://youtu.be/NXkzgfWHQnA
And follow us to stay updated: https://www.youtube.com/GlobalOneMedia